Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 55–57.

https://doi.org/10.1182/blood-2020-139492

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

Blood (2019) 134 (Supplement_1): 4227.

https://doi.org/10.1182/blood-2019-128075

Published: 2019

Journal Articles

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Johann-Christoph Jann, Johanna Flach, PhD, Antje Knaflic, Eva Altrock, PhD, Nanni Schmitt, MSc, Alexander Streuer, Justine Danner, Franziska Hofmann, Verena Nowak, Nina Draeger, Julia Obländer, Iris Palme, Patrick Wuchter, MD, Ahmed Jawhar, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD PhD, Daniel Nowak, MD

Blood (2019) 134 (Supplement_1): 4218.

https://doi.org/10.1182/blood-2019-126431

Published: 2019

Journal Articles

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Nanni Schmitt, MSc, Eva Altrock, PhD, Johann-Christoph Jann, MD, Johanna Flach, PhD, Carla Sens-Albert, PhD, Justine Danner, Stefanie Uhlig, Jovita Pressler, Iris Palme, Verena Nowak, Julia Obländer, Lena Drangmeister, MD, Franziska La Meir, MD, Georgia Metzgeroth, MD, Florian Nolte, MD, Wolf-Karsten Hofmann, Daniel Nowak, MD

Blood (2018) 132 (Supplement 1): 942.

https://doi.org/10.1182/blood-2018-99-116341

Published: 2018

Journal Articles

Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study)

Blood (2018) 132 (Supplement 1): 208.

https://doi.org/10.1182/blood-2018-99-115932

Published: 2018

Journal Articles

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Blood (2017) 130 (Supplement 1): 2916.

https://doi.org/10.1182/blood.V130.Suppl_1.2916.2916

Published: 2017

Journal Articles

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Uwe Platzbecker, MD, Eva Lengfelder, MD, Katharina S Goetze, MD, Christoph Röllig, MD, Michael Kramer, Michaela Sauer, Nadine Albers, Michael Heuser, Hartmut Link, MD PhD, Kerstin Schäfer-Eckart, MD, Sonja Martin, MD, Stefan W. Krause, MD, Mathias Hänel, MD, Tilmann Bochtler, MD, Andreas Jakob, MD, Albrecht Reichle, MD, Harald Biersack, MD, Claudia D. Baldus, MD, Martin Goerner, MD, Nadezda Basara, MD, Joerg Mezger, MD, Ralph Naumann, MD, Dorit Kuerschner, MD, Maike de Wit, Florian Nolte, MD, Mark Ringhoffer, MD, Hans-Joachim Tischler, MD, Jochen Greiner, Stephan Kremers, Sigrid Machherndl-Spandl, MD, Elisabeth Koller, MD, Mohammad Amen Wattad, MD, Gregor Aschauer, MD, Markus Radsak, MD, Thomas Kubin, MD, Helmut Salih, MD, Frank Heits, MD, Dominik Wolf, MD, Christian Thiede, MD, Hubert Serve, MD, Ulrich Duehrsen, MD, Andreas Hochhaus, MD, Tim H. Brümmendorf, MD, Martin Bornhäuser, MD, Hartmut Döhner, MD, Gerhard Ehninger, MD, Richard F. Schlenk, MD

Blood (2016) 128 (22): 2815.

https://doi.org/10.1182/blood.V128.22.2815.2815

Published: 2016

Journal Articles

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Johann-Christoph Jann, Maximilian Mossner, Florian Nolte, MD, Tobias Boch, MD, Verena Nowak, Iris Palme, Julia Obländer, Jovita Pressler, Christina Xanthopoulos, Henning Röhl, MD, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD

Blood (2016) 128 (22): 4300.

https://doi.org/10.1182/blood.V128.22.4300.4300

Published: 2016

Journal Articles

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Tobias Boch, MD, Thomas Luft, MD PhD, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, MD, Christine Folz, Jennifer Klemmer, Susanne Brendel, Harald Fricke, MD, Claudia Kunz, PhD, Wolf-Karsten Hofmann, MD, Florian Nolte, MD

Blood (2016) 128 (22): 228.

https://doi.org/10.1182/blood.V128.22.228.228

Published: 2016

Journal Articles

Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)

Maximilian Mossner, Alexandra Stoehr, Johann-Christoph Jann, Florian Nolte, MD, Verena Nowak, Julia Oblaender, Jovita Pressler, Christina Xanthopoulos, Iris Palme, Claudia D Baldus, MD, Torsten Schulze, MD, Tobias Boch, MD, Georgia Metzgeroth, MD, Martin Neumann, MD, Wolf-Karsten Hofmann, MD, Daniel Nowak, MD

Blood (2015) 126 (23): 2859.

https://doi.org/10.1182/blood.V126.23.2859.2859

Published: 2015

Journal Articles

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

Blood (2013) 122 (21): 2759.

https://doi.org/10.1182/blood.V122.21.2759.2759

Published: 2013

Journal Articles

Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes

Maximilian Mossner, Axel Wilbertz, Stephanie Fey, Julia Obländer, Verena Nowak, Jovita Vogler, Florian Nolte, MD, Ralf Bieber, Wolf-Karsten Hofmann, MD, Mark Reinwald, MD, Daniel Nowak, MD

Blood (2013) 122 (21): 1561.

https://doi.org/10.1182/blood.V122.21.1561.1561

Published: 2013

Journal Articles

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Florian Nolte, MD, Claudia Kunz, Stephanie Fey, Julia Obländer, Susanne Brendel, Marion Klaumünzer, Maximilian Mossner, Johann-Christoph Jann, Stefanie Uhlig, Daniel Nowak, MD, Harald Fricke, MD, Wolf-Karsten Hofmann, MD

Blood (2013) 122 (21): 1562.

https://doi.org/10.1182/blood.V122.21.1562.1562

Published: 2013

Journal Articles

Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response – , Evolutionary -, and Remission Patterns and No Increased Karyotype Evolution (KE)

Katayoon Shirneshan, PhD, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Aristoteles Giagounidis, MD, Katharina Götze, M.D., Richard F. Schlenk, MD, Michael Lübbert, MD, Gesine Bug, MD, PhD, Friederike Braulke, Julie Schanz, MD, Ulrich Germing, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2783.

https://doi.org/10.1182/blood.V122.21.2783.2783

Published: 2013

Journal Articles

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Julie Schanz, MD, Friederike Braulke, Katayoon Shirneshan, PhD, Kathrin Nachtkamp, MD, Ulrich Germing, MD, Stephan Schmitz, MD, Peter Haas, MD, Michael Lübbert, MD, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2784.

https://doi.org/10.1182/blood.V122.21.2784.2784

Published: 2013

Journal Articles

Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG

Martin Wermke, MD, Claudia Schuster, Claudia Schönefeldt, Christiane Jakob, MD, Malte von Bonin, MD, Florian Nolte, MD, Philipp Kiewe, MD, Regina Herbst, MD, Ulrich Germing, MD, Michael Aigner, PhD, Detlef Haase, MD, Ina-Maria Klut, PhD, Nadja Jaekel, Gustavo Baretton, MD, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Wolf-Karsten Hofmann, MD, Uwe Platzbecker, MD, PhD

Blood (2013) 122 (21): 2808.

https://doi.org/10.1182/blood.V122.21.2808.2808

Published: 2013

Journal Articles

A Risk Score Integrating BAALC, ERG and WT1 Expression Can Be Used To Improve Risk Stratification In Acute Promyelocytic Leukemia

Anna Hecht, Florian Nolte, MD, Daniel Nowak, MD, Verena Nowak, Benjamin Hanfstein, MD, Thomas Büchner, MD, Karsten Spiekermann, MD, Wolf-Karsten Hofmann, MD, Eva Lengfelder, MD

Blood (2013) 122 (21): 1323.

https://doi.org/10.1182/blood.V122.21.1323.1323

Published: 2013

Journal Articles

Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia

Johann-Christoph Jann, Daniel Nowak, MD, Florian Nolte, MD, Claudia Haferlach, MD, Marita Staller, Verena Nowak, Bettina Zens, Katja Müdder, Corinna Klein, Julia Obländer, Stephanie Fey, Jovita Vogler, Alice Fabarius, PhD, Alexander Kohlmann, PhD, Wolf-Karsten Hofmann, MD, Andreas Trumpp, PhD, Hind Medyouf, PhD, Maximilian Mossner

Blood (2013) 122 (21): 519.

https://doi.org/10.1182/blood.V122.21.519.519

Published: 2013

NARROW

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Comparison of Four Different Humanized Hematopoietic Niche Xenotransplantation Methods to Engraft Myelodysplastic Syndromes (MDS)

R-Loops-Induced ATR Signaling As a Potential Therapeutic Target in Myelodysplastic Syndrome

Placebo Controlled Functional Analysis of Eltrombopag in a Preclinical Xenograft Model of Myelodysplastic Syndromes (MDS)

Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study)

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)

TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial

Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG

A Risk Score Integrating BAALC, ERG and WT1 Expression Can Be Used To Improve Risk Stratification In Acute Promyelocytic Leukemia

Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only